As the market digests this HUGE news and we await "detailed study findings will be submitted for publication in a peer-reviewed scientific journal", I would expect to see some extreme to continue.
I have a long position ACB $8.20 and I actively swing-trade as opportunities arise. Pull-back(s) such as where we are now are the opportunities I seek.
I expect to see many upgrades in the near future and the possibility(s) of partnerships could be announced anytime. As with any small-cap bio stock, dilution is a possibility in order to fund ongoing phase 1 & 2 clinical trials or future phase 3 trials.
**Note** I am particularly interested in the possibility of a gap (getting filled) that formed on the on July 23rd (phase 2 data released) @ $11.60 - $12.00.
Hope you enjoy the chart and have great trades in the future.